KCNA5: Potassium voltage-gated channel subfamily A member 5
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on KCNA5, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Vernakalant | Approved | Astellas Pharma | Small molecule | BlockerVoltage-gated potassium channel subunit Kv1.5 blocker | 1 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients | Vernakalant | Phase 3 | Not yet recruiting | University of Calgary | Feb 10, 2021 |
- Familial atrial fibrillation0.62
- Lambert-Eaton myasthenic syndrome0.56
- Myasthenia gravis0.56
- Atrial fibrillation0.54
- Cardiac arrhythmia0.50
- Congenital myasthenic syndrome0.49
- Muscle weakness0.46
- Neoplasm0.39
- Cancer0.39
- Autoimmune disease0.37
- Nervous system neoplasm0.37
- Autoimmune disorder of the nervous system0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4306, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P22460, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets